KESTRA MEDICAL TECHNOLOGIES, LTD.
Last · NASDAQ$25.47-1.50 (-5.56%)close · yahoo · 11h ago
Market cap$1.52B59.6M sh
P/E · TTM-9.5fwd -12.4 · eps -2.67 · loss
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$17.34$30.00
Volume237.4Ksession
| Revenue | $95.1M |
|---|---|
| Operating income | $-134.7M |
| Net income | $-131.6M |
| Free cash flow | $-116.6M |
| Operating margin | -141.6% |
| Net margin | -138.4% |
| Return on equity | -50.7% |
| Period | 2026 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-07-14
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Sbc Revenue High — SBC/Revenue 35.4%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -138.4%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -85.9%
- Cash Runway Low — Cash runway ~1.2 years
- Accumulated Deficit High — Accumulated deficit / equity 251%
Upcoming earnings
9:00 PM UTC+1
Period
Oct 2026
Est. EPS
−$0.61
Est. revenue
32.0M
Earnings transcripts
Press & signals
- GlobeNewswire
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
- GlobeNewswire
Kestra Names Daniel Finney Vice President of Research & Development
- GlobeNewswire
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags